Vertex(VRTX) - 2024 Q4 - Earnings Call Presentation

Financial Performance - Total product revenues for Q4 2024 reached $2.91 billion, a 16% increase compared to Q4 2023[7,40] - Full year 2024 total product revenues were $11.02 billion, up 12% from full year 2023[7,40] - TRIKAFTA/KAFTRIO revenues for full year 2024 were $10.24 billion[40] - Combined non-GAAP R&D and SG&A expenses for full year 2024 were $4.19 billion[40] - Non-GAAP operating income for full year 2024 was $696 million, resulting in a 6% non-GAAP operating margin[40] Product and Pipeline Updates - ALYFTREK was approved in the U S for patients with CF ages 6+[8,12] - JOURNAVX was approved in the U S for moderate to severe acute pain[7] - CASGEVY has achieved over 50 ATC activations and over 50 cell collections[7,34] - The company anticipates 5 launches in 5 years (by 2028)[10] - 2025 financial guidance projects total revenue between $11 75 billion and $12 0 billion[42]